Galecto, Inc. Files Q1 2025 10-Q
Ticker: DMRA · Form: 10-Q · Filed: May 8, 2025 · CIK: 1800315
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals, stock-options
TL;DR
Galecto's Q1 2025 10-Q is in. Check R&D spend & stock plans.
AI Summary
Galecto, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information, including stock option and grant plans from 2020 and 2022, and mentions research and development expenses for the first quarter of 2024. The company is incorporated in Delaware and headquartered in Boston, MA.
Why It Matters
This filing provides a snapshot of Galecto's financial health and operational activities for the first quarter of 2025, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Galecto faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- Q1 2025 — Reporting Period (The period covered by this 10-Q filing.)
- 2020 — Stock Plan Year (Refers to the 'TwoThousandTwentyStockOptionAndGrantPlanMember'.)
- 2022 — Inducement Plan Year (Refers to the 'TwoThousandTwentyTwoInducementPla'.)
Key Players & Entities
- Galecto, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250508 (date) — Filing date
- Boston, MA (location) — Company headquarters
- 2020 (date) — Year of stock option and grant plan
- 2022 (date) — Year of inducement plan
- 2024 (date) — Year for R&D expense reporting
FAQ
What were Galecto's research and development expenses for the first quarter of 2024?
The filing indicates research and development expenses for the period of January 1, 2024 to March 31, 2024.
What is the company's fiscal year end?
Galecto, Inc.'s fiscal year ends on December 31st.
When was the company formerly known as Galecto Inc. renamed?
The date of the name change from Galecto Inc. to Galecto, Inc. was January 16, 2020.
What type of stock options and grants are mentioned in the filing?
The filing mentions 'TwoThousandTwentyStockOptionAndGrantPlanMember' and 'us-gaap:StockOptionMember'.
What is the company's SIC code?
The Standard Industrial Classification code for Galecto, Inc. is 2834, Pharmaceutical Preparations.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Galecto, Inc. (DMRA).